University Of Turku
- Address
- lock Available on a paid plan
Neoplasms and Immune System Diseases
Research at the University Of Turku focuses on acute lymphoblastic leukemia in infants, with studies aimed at improving survival outcomes and strengthening treatment effectiveness for newly diagnosed cases.
- Evaluating new approaches for infant acute lymphoblastic leukemia
- Measuring whether care can improve event-free survival
- Comparing results with earlier treatment experience
This area reflects a strong interest in pediatric cancer research, combining clinical care with efforts to refine treatment strategies for rare and high-risk blood cancers.
Nervous System Diseases
Clinical trials in Clinical Neurosciences examine progressive multiple sclerosis, with the goal of better understanding and reducing ongoing inflammation in the brain and white matter.
- Studying progressive multiple sclerosis
- Assessing changes in brain inflammation markers
- Exploring whether treatment can improve disease control
At University Of Turku, this work supports research into new ways to monitor and potentially ease neuroinflammatory activity in chronic neurological disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Of Turku
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Istradefylline for Reducing Microglial Activation in Progressive Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial | University Of Turku | Phase II | Recruiting | Mar 2025 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Asparaginase | 1 | Unknown | 2022-12-15 | 2022-12-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.